GB9513371D0
(en)
*
|
1995-06-30 |
1995-09-06 |
Biocine Spa |
Immunogenic detoxified mutant toxins
|
ATE275970T1
(de)
|
1993-10-05 |
2004-10-15 |
Celltech Pharmaceuticals Ltd |
Impfstoffzusammensetzungen
|
GB9326174D0
(en)
|
1993-12-22 |
1994-02-23 |
Biocine Sclavo |
Mucosal adjuvant
|
US5981730A
(en)
*
|
1994-04-13 |
1999-11-09 |
The General Hospital Corporation |
RPS gene family, primers, probes, and detection methods
|
US6436407B1
(en)
|
1994-08-26 |
2002-08-20 |
The Administrators Of The Tulane Educational Fund |
Mutant enterotoxin effective as a non-toxic adjuvant
|
US6019982A
(en)
|
1994-08-26 |
2000-02-01 |
The Administrators Of The Tulane Educational Fund |
Mutant enterotoxin effective as a non-toxic oral adjuvant
|
GB9603314D0
(en)
*
|
1996-02-16 |
1996-04-17 |
Biocine Spa |
Immunogenic detoxified mutant toxins
|
GB9622660D0
(en)
|
1996-10-31 |
1997-01-08 |
Biocine Spa |
Immunogenic detoxified mutant toxin
|
US20060002949A1
(en)
|
1996-11-14 |
2006-01-05 |
Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. |
Transcutaneous immunization without heterologous adjuvant
|
US6797276B1
(en)
|
1996-11-14 |
2004-09-28 |
The United States Of America As Represented By The Secretary Of The Army |
Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
|
US6036953A
(en)
*
|
1996-11-29 |
2000-03-14 |
The General Hospital Corporation |
Heterologous antigens in live cell V. cholerae strains
|
WO1998032461A1
(en)
*
|
1997-01-29 |
1998-07-30 |
The Administrators Of The Tulane Educational Fund |
Mutant enterotoxin effective as a non-toxic adjuvant for hiv
|
US6818222B1
(en)
*
|
1997-03-21 |
2004-11-16 |
Chiron Corporation |
Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
|
EP1486215A3
(en)
*
|
1997-03-21 |
2006-04-12 |
Chiron Corporation |
Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
|
EP0887403A3
(en)
*
|
1997-06-27 |
2000-12-06 |
Chiron S.P.A. |
Attenuated Vibrio cholerae strains
|
EP1007546B1
(en)
|
1997-08-27 |
2009-01-21 |
Novartis Vaccines and Diagnostics, Inc. |
Molecular mimetics of meningococcal b epitopes
|
AU3089599A
(en)
*
|
1998-03-18 |
1999-10-11 |
Smithkline Beecham Corporation |
Production of purified mutant enterotoxin for use as an adjuvant
|
US6033673A
(en)
*
|
1998-03-18 |
2000-03-07 |
The Administrators Of Tulane Educational Fund |
Double mutant enterotoxin for use as an adjuvant
|
CA2335487A1
(en)
|
1998-06-19 |
1999-12-23 |
Merieux Oravax |
Lt and ct in parenteral immunization methods against helicobacter infection
|
DE19851282A1
(de)
*
|
1998-11-06 |
2000-05-11 |
Schweiz Serum & Impfinst |
Zusammensetzung einer pharmazeutisch wirksamen Substanz, appliziert in einem spezifischen Delivery-System zur Prävention und Behandlung von Infektions-Krankheiten
|
BR9916515A
(pt)
*
|
1998-12-22 |
2001-11-06 |
Thompson Boyce Plant Res |
Polinucleotìdeo, vetor de expressão, células de e. coli e de agrobacterium tumefaciens transformadas com o vetor de expressão, célula de planta transgênica, semente de planta transgênica, célula eucariótica transgênica, composição imunogênica, método de evocar uma resposta imune em um animal ou ser humano, planta transgênica, e, adjuvante
|
CA2360347C
(en)
|
1998-12-31 |
2013-05-07 |
Chiron Corporation |
Improved expression of hiv polypeptides and production of virus-like particles
|
US7935805B1
(en)
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
EP1574210B1
(en)
|
1999-02-26 |
2016-04-06 |
Novartis Vaccines and Diagnostics, Inc. |
Microemulsions with adsorbed macromolecules
|
ATE481108T1
(de)
|
1999-02-26 |
2010-10-15 |
Novartis Vaccines & Diagnostic |
Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenen
|
US7115730B1
(en)
|
1999-04-27 |
2006-10-03 |
Chiron Srl |
Immunogenic detoxified mutant E. coli LT-A-toxin
|
GB9919468D0
(en)
|
1999-08-17 |
1999-10-20 |
Smithkline Beecham Biolog |
Vaccine
|
US7722887B1
(en)
*
|
1999-09-15 |
2010-05-25 |
Mogam Biotechnology Research Institute |
Detoxified mutants of escherichia coli heat-labile enterotoxin
|
US7186560B2
(en)
*
|
1999-09-21 |
2007-03-06 |
Rutgers, The State University Of New Jersey |
High level expression of immunogenic proteins in the plastids of higher plants
|
CA2385484A1
(en)
*
|
1999-09-21 |
2001-03-29 |
Rutgers, The State University Of New Jersey |
Site-specific recombination system to manipulate the plastid genome of higher plants
|
GB9923060D0
(en)
|
1999-09-29 |
1999-12-01 |
Chiron Spa |
Vaccine
|
US7384640B1
(en)
|
1999-09-30 |
2008-06-10 |
Wyeth Holdings Corporation |
Mutant cholera holotoxin as an adjuvant
|
EP1221972B1
(en)
|
1999-10-26 |
2011-01-12 |
Novartis Vaccines and Diagnostics, Inc. |
Plant lectins as mucosal adjuvants
|
US20020142006A1
(en)
*
|
2000-03-17 |
2002-10-03 |
Mcghee Jerry R. |
Chimeric nontoxic mutants of enterotoxins as mucosal adjuvants for cell-mediated or humoral immunity
|
US7063852B2
(en)
|
2000-05-19 |
2006-06-20 |
The Administrators Of The Tulane Educational Fund |
Hybrid LT-A/CT-B holotoxin for use as an adjuvant
|
CA2430379A1
(en)
|
2000-12-07 |
2002-06-13 |
Chiron Corporation |
Endogenous retroviruses up-regulated in prostate cancer
|
DE60239317D1
(de)
|
2001-01-12 |
2011-04-14 |
Novartis Vaccines & Diagnostic |
Nukleinsäure mukosale immunisierung
|
JP2004529906A
(ja)
|
2001-03-19 |
2004-09-30 |
イオマイ コーポレイシヨン |
経皮的免疫賦活
|
US7534936B2
(en)
*
|
2001-03-29 |
2009-05-19 |
Rutgers, The State University Of New Jersey |
Transgenic plants having transformed plastid genomes and progeny thereof
|
ES2533085T3
(es)
|
2001-05-22 |
2015-04-07 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Desarrollo de mutaciones útiles para atenuar virus del dengue y virus del dengue quiméricos
|
IL159209A0
(en)
*
|
2001-06-07 |
2004-06-01 |
Wyeth Corp |
Mutant forms of cholera holotoxin as an adjuvant
|
CN1977971A
(zh)
|
2001-06-07 |
2007-06-13 |
惠氏控股有限公司 |
作为佐剂的霍乱全毒素的突变体形式
|
US8481043B2
(en)
|
2001-06-22 |
2013-07-09 |
Cpex Pharmaceuticals, Inc. |
Nasal immunization
|
AU2002320314A1
(en)
|
2001-07-05 |
2003-01-21 |
Chiron, Corporation |
Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
|
EP1409694A4
(en)
|
2001-07-05 |
2006-02-08 |
Chiron Corp |
POLYNUCLEOTIDES ENCODING ANTIGENIC POLYPEPTIDES OF HIV SUBTYPE B AND / OR SUBTYPE C, POLYPEPTIDES AND USES THEREOF
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
WO2003010194A2
(en)
|
2001-07-27 |
2003-02-06 |
Chiron Srl. |
Meningococcus adhesins nada, app and orf 40
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
MX339524B
(es)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
US7501134B2
(en)
|
2002-02-20 |
2009-03-10 |
Novartis Vaccines And Diagnostics, Inc. |
Microparticles with adsorbed polypeptide-containing molecules
|
JP2005532789A
(ja)
|
2002-03-15 |
2005-11-04 |
ワイス・ホールデイングス・コーポレーシヨン |
減少した酵素活性を有する型別不能なインフルエンザ菌(Haemophilusinfluenza)のP4タンパク質の変異体
|
AU2003276679A1
(en)
|
2002-06-13 |
2003-12-31 |
Chiron Corporation |
Vectors for expression of hml-2 polypeptides
|
ES2320119T3
(es)
*
|
2002-08-27 |
2009-05-19 |
Dow Agrosciences Llc |
Uso de toxina remolabil de escherichia coli como adyvante en aves de corral.
|
AU2003279770A1
(en)
|
2002-10-01 |
2004-04-23 |
Novartis Vaccines And Diagnostics, Inc. |
Anti-cancer and anti-infectious disease compositions and methods for using same
|
ES2649048T3
(es)
|
2002-11-01 |
2018-01-09 |
Glaxosmithkline Biologicals S.A. |
Procedimiento de secado
|
WO2004043286A2
(en)
*
|
2002-11-14 |
2004-05-27 |
Pfizer Products Inc. |
Use of rmlt as a marker antigen for vaccines and as a synergistic adjuvant with amphigen
|
JP2006520746A
(ja)
|
2002-12-27 |
2006-09-14 |
カイロン コーポレイション |
リン脂質を含む免疫原性組成物
|
US6743002B1
(en)
*
|
2003-02-03 |
2004-06-01 |
Eaton Corporation |
Rotary fluid pressure device and improved integral brake assembly
|
US20040171565A1
(en)
*
|
2003-02-14 |
2004-09-02 |
David Hone |
DNA vaccines that expresses mutant ADP-ribosyltransferase toxins which display reduced, or are devoid of, ADP-ribosyltransferase activity
|
WO2004078935A2
(en)
*
|
2003-03-03 |
2004-09-16 |
Rutgers, The State University Of New Jersey |
Removal of plastid sequences by transiently expressed site-specific recombinases
|
US20060251675A1
(en)
*
|
2003-03-17 |
2006-11-09 |
Michael Hagen |
Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
|
GB0308198D0
(en)
*
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
US7731967B2
(en)
|
2003-04-30 |
2010-06-08 |
Novartis Vaccines And Diagnostics, Inc. |
Compositions for inducing immune responses
|
PL1631264T5
(pl)
|
2003-06-02 |
2018-09-28 |
Glaxosmithkline Biologicals Sa |
Kompozycje immunogenne oparte na biodegradowalnych mikrocząstkach zawierających toksoid błonicy i tężca
|
GB0313242D0
(en)
*
|
2003-06-09 |
2003-07-16 |
Imp College Innovations Ltd |
Pulmonary immunopathology
|
RU2368392C2
(ru)
|
2003-09-02 |
2009-09-27 |
ГлаксоСмитКлайн Байолоджикалз с.а. |
Применение аттенуированного ротавирусного штамма серотипа g1 в изготовлении композиции для индукции иммунного ответа на ротавирусную инфекцию
|
US20100015211A1
(en)
|
2004-11-01 |
2010-01-21 |
Barnett Susan W |
Combination Approaches For Generating Immune Responses
|
GB0503337D0
(en)
|
2005-02-17 |
2005-03-23 |
Glaxosmithkline Biolog Sa |
Compositions
|
CN102716480B
(zh)
|
2005-04-08 |
2023-03-21 |
惠氏有限责任公司 |
多价肺炎球菌多糖-蛋白质缀合物组合物
|
EP2357000A1
(en)
|
2005-10-18 |
2011-08-17 |
Novartis Vaccines and Diagnostics, Inc. |
Mucosal and systemic immunizations with alphavirus replicon particles
|
US8143474B2
(en)
*
|
2006-04-18 |
2012-03-27 |
Rutgers, The State University Of New Jersey |
Compositions and methods for increasing transgene expression in the plastids of higher plants
|
TW200806315A
(en)
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
US8926993B2
(en)
|
2006-07-17 |
2015-01-06 |
Aduro Biotech |
Methods and compositions using Listeria for enhancing immunogenicity by prime boost
|
US20090010966A1
(en)
*
|
2007-06-21 |
2009-01-08 |
Angelica Therapeutics, Inc. |
Modified diphtheria toxins
|
AU2008335457B2
(en)
|
2007-12-07 |
2015-04-16 |
Glaxosmithkline Biologicals S.A. |
Compositions for inducing immune responses
|
EP2268297A4
(en)
*
|
2008-02-29 |
2011-11-16 |
Angelica Therapeutics Inc |
MODIFIED TOXINS
|
US9415006B2
(en)
|
2008-05-23 |
2016-08-16 |
The Regents Of The University Of Michigan |
Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
|
KR20110031343A
(ko)
|
2008-06-20 |
2011-03-25 |
와이어쓰 엘엘씨 |
베타-용혈성 스트렙토코커스 균주로부터 유래된 orf1358을 사용하는 조성물 및 방법
|
WO2010036938A2
(en)
|
2008-09-26 |
2010-04-01 |
Nanobio Corporation |
Nanoemulsion therapeutic compositions and methods of using the same
|
EP2350132A4
(en)
*
|
2008-10-21 |
2013-05-29 |
Internat Vaccine Inst |
THE A1 GROUP OF THE A SUB-UNIT OF CHOLERATOXIN AS ADJUVANS FOR MUCOSAL AND SYSTEMIC VACCINES
|
AU2010203223B9
(en)
|
2009-01-05 |
2015-10-08 |
Epitogenesis Inc. |
Adjuvant compositions and methods of use
|
US8765171B2
(en)
|
2009-03-09 |
2014-07-01 |
The Regents Of The University Of California |
Methods and compositions for liposomal formulation of antigens and uses thereof
|
JP6110140B2
(ja)
|
2009-06-16 |
2017-04-05 |
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン |
ナノエマルションワクチン
|
JP2012530785A
(ja)
|
2009-06-22 |
2012-12-06 |
ワイス・エルエルシー |
組成物および黄色ブドウ球菌(Staphylococcusaureus)血清型5および8莢膜多糖コンジュゲート免疫原性組成物を調製するための方法
|
WO2010151544A1
(en)
|
2009-06-22 |
2010-12-29 |
Wyeth Llc |
Immunogenic compositions of staphylococcus aureus antigens
|
TW201103980A
(en)
|
2009-07-08 |
2011-02-01 |
Abbott Biologicals Bv |
Viral vaccine and use thereof
|
US8241608B2
(en)
*
|
2010-03-23 |
2012-08-14 |
Development Center For Biotechnology |
Treating allergy with detoxified E. coli heat-labile enterotoxin
|
US9161974B2
(en)
|
2010-05-23 |
2015-10-20 |
Aduro Biotech, Inc. |
Methods and compositions using listeria for adjuvant treatment of cancer
|
PL3170508T3
(pl)
|
2010-06-04 |
2020-04-30 |
Wyeth Llc |
Preparaty szczepionek
|
US8658603B2
(en)
|
2010-06-16 |
2014-02-25 |
The Regents Of The University Of Michigan |
Compositions and methods for inducing an immune response
|
ES2850973T3
(es)
|
2010-08-23 |
2021-09-01 |
Wyeth Llc |
Formulaciones estables de antígenos rLP2086 de Neisseria meningitidis
|
WO2012032489A1
(en)
|
2010-09-10 |
2012-03-15 |
Wyeth Llc |
Non-lipidated variants of neisseria meningitidis orf2086 antigens
|
DK3150222T3
(da)
|
2010-12-22 |
2020-01-27 |
Wyeth Llc |
Stabile immunogene sammensætninger af staphylococcus aureus-antigener
|
EA034702B1
(ru)
|
2011-04-26 |
2020-03-10 |
Молекулар Экспресс, Инк. |
Липосомные композиции
|
BR112013032410A2
(pt)
|
2011-06-24 |
2017-01-17 |
Epitogenesis Inc |
composições farmacêuticas compreendendo uma combinação de veículos, vitaminas, taninos e flavonoides de seleção como imunomoduladores específicos de antígeno
|
CA2855826A1
(en)
|
2011-11-14 |
2013-05-23 |
Novartis Ag |
Immunogenic complexes of polyanionic carbomers and env polypeptides and methods of manufacture and use thereof
|
NZ628449A
(en)
|
2012-03-09 |
2016-04-29 |
Pfizer |
Neisseria meningitidis compositions and methods thereof
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
EP2870238A4
(en)
|
2012-07-05 |
2016-03-09 |
Ohio State Innovation Foundation |
COMPOSITIONS AND METHODS ASSOCIATED WITH VIRAL VACCINES
|
WO2014044690A1
(en)
|
2012-09-18 |
2014-03-27 |
Valneva Austria Gmbh |
Improved vaccines
|
PL2912186T3
(pl)
|
2012-10-24 |
2021-06-14 |
Platelet Targeted Therapeutics Llc |
Leczenie ukierunkowane na płytki krwi
|
WO2014097099A2
(en)
|
2012-12-20 |
2014-06-26 |
Pfizer Inc. |
Glycoconjugation process
|
CN105188747A
(zh)
|
2013-02-01 |
2015-12-23 |
葛兰素史密斯克莱生物公司 |
包含toll样受体激动剂的免疫组合物的皮内递送
|
JP6446377B2
(ja)
|
2013-03-08 |
2018-12-26 |
ファイザー・インク |
免疫原性融合ポリペプチド
|
US10059750B2
(en)
|
2013-03-15 |
2018-08-28 |
Angelica Therapeutics, Inc. |
Modified toxins
|
CA2923129C
(en)
|
2013-09-08 |
2020-06-09 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
KR101977449B1
(ko)
|
2013-11-01 |
2019-05-10 |
유니버시티에트 이 오슬로 |
알부민 변이체 및 이의 용도
|
EP3068426B1
(en)
|
2013-11-13 |
2020-02-12 |
University Of Oslo |
Outer membrane vesicles and uses thereof
|
US11452767B2
(en)
|
2013-11-15 |
2022-09-27 |
Oslo Universitetssykehus Hf |
CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
|
WO2016130569A1
(en)
|
2015-02-09 |
2016-08-18 |
Mj Biologics, Inc. |
A composition comprising pedv antigens and methods for making and using the composition
|
US10034934B2
(en)
|
2014-03-11 |
2018-07-31 |
Regents Of The University Of Minnesota |
Porcine epidemic diarrhea virus vaccines and methods of use thereof
|
ES2924988T3
(es)
|
2014-10-10 |
2022-10-13 |
Univ Michigan Regents |
Composiciones con nanoemulsiones para prevenir, inhibir o eliminar una enfermedad alérgica e inflamatoria
|
BR112017017460A2
(pt)
|
2015-02-19 |
2018-04-10 |
Pfizer Inc. |
composições de neisseria meningitidis e métodos das mesmas
|
CN107530416A
(zh)
|
2015-03-05 |
2018-01-02 |
西北大学 |
非神经侵染的病毒及其用途
|
WO2016179034A2
(en)
|
2015-05-01 |
2016-11-10 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for stimulating immune response using potent immunostimulatory rna motifs
|
IL297740A
(en)
|
2015-05-04 |
2022-12-01 |
Pfizer |
Protein-polysaccharide conjugates of group b streptococcus, methods for preparing the conjugates, immunogenic preparations containing conjugates and their uses
|
US11324816B2
(en)
|
2015-08-31 |
2022-05-10 |
Technovax, Inc. |
Human respiratory syncytial virus (HRSV) virus-like particles (VLPS) based vaccine
|
US10548970B2
(en)
|
2015-10-05 |
2020-02-04 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Human rotavirus G9P[6] strain and use as a vaccine
|
WO2017158421A1
(en)
|
2016-03-14 |
2017-09-21 |
University Of Oslo |
Anti-viral engineered immunoglobulins
|
JP7155008B2
(ja)
|
2016-03-14 |
2022-10-18 |
ウニヴァーシテテット イ オスロ |
変化されたFcRnを有する改変された免疫グロブリン
|
WO2017201390A1
(en)
|
2016-05-19 |
2017-11-23 |
The Regents Of The University Of Michigan |
Novel adjuvant compositions
|
US11033615B2
(en)
|
2016-05-31 |
2021-06-15 |
The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland |
Zika virus vaccine and methods of production
|
US11780924B2
(en)
|
2016-06-21 |
2023-10-10 |
University Of Oslo |
HLA binding vaccine moieties and uses thereof
|
GB201614799D0
(en)
|
2016-09-01 |
2016-10-19 |
Glaxosmithkline Biologicals Sa |
Compositions
|
US10751402B2
(en)
|
2016-11-09 |
2020-08-25 |
Pfizer Inc. |
Immunogenic compositions and uses thereof
|
WO2018096396A1
(en)
|
2016-11-22 |
2018-05-31 |
University Of Oslo |
Albumin variants and uses thereof
|
CN110234658B
(zh)
|
2017-01-31 |
2024-03-12 |
辉瑞大药厂 |
脑膜炎奈瑟菌组合物及其使用方法
|
US10525119B2
(en)
|
2017-03-31 |
2020-01-07 |
Boston Medical Center Corporation |
Methods and compositions using highly conserved pneumococcal surface proteins
|
US12005112B2
(en)
|
2017-09-07 |
2024-06-11 |
University Of Oslo |
Vaccine molecules
|
WO2019048928A1
(en)
|
2017-09-07 |
2019-03-14 |
University Of Oslo |
VACCINE MOLECULES
|
NL2030835B1
(en)
|
2020-01-24 |
2022-12-29 |
Aim Immunotech Inc |
Methods, compositions, and vaccinces for treating a virus infection
|
US20230146256A1
(en)
|
2020-04-17 |
2023-05-11 |
Regents Of The University Of Minnesota |
SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF
|
EP4203995A1
(en)
|
2020-08-26 |
2023-07-05 |
Pfizer Inc. |
Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
|
EP4313132A1
(en)
|
2021-03-31 |
2024-02-07 |
Vib Vzw |
Vaccine compositions for trypanosomatids
|
CN113788893B
(zh)
*
|
2021-08-11 |
2022-08-09 |
中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) |
一种快速富集霍乱弧菌的偶联特异性单克隆抗体的免疫磁珠及其制备方法
|